6歳までの第二言語（L2）学習者への語彙介入 要点 - このレビューに含まれる研究では、第二言語学習者に対する語彙介入は、子どもの第二言語の語彙学習に役立つかもしれないが、リスニングの理解力にはほとんど効果がないことが示唆されている。ただし、そのエビデンスは非常に不確かである。語彙の介入は、おそらくストーリーテリングのスキルを向上させるだろう。 - より長期的な効果を調査するために、第二言語学習者を長期にわたって追跡調査する、より質の高い研究が必要である。これには米国外の学習者も含まれるべきだ。 なぜこのレビューが重要なのか？ 第二言語（L2）の能力が限られていると、学業成績に悪影響を及ぼす可能性がある。なぜなら、指導を受ける言語の語彙知識は、読解力、教室での学習、多様性の受け入れにおいて中心となるものだからである。成人期には、（母語（L1）の継続的な言語能力だけでなく）地域言語の熟達は、雇用、良好な人間関係、社会参加の予測材料となる。 レビューの目的は何か？ 主な目的は、6歳までの第二言語学習者を対象とした語彙力介入が、語彙力と社会的および情動的なウェル・ビーイング（感情を理解し管理する能力、責任ある決断を下す能力、人間関係を構築し維持する能力、他者を理解し共感する能力）に及ぼす即時的および長期的な影響を調べることであった。第二の目的は、第二言語の語彙介入と第二言語学習者の一般...

Tuesday, August 1, 2023

Specifications: Permanent – Full Time (Hybrid Role, 3 days office and 2 days WFH)
Salary: £60,000 (Paid in DKK, as per market exchange rate) per annum
Location: Copenhagen, Denmark
Closing date: Aug 14, 2023
 
Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world.” Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

As development team lead, you will manage an Agile/Scrum software development team (3 developers, 1 test engineer) who develop web applications that accelerate the production of systematic reviews of health evidence. You will support the team in their work, coordinate with product owners on timelines, and contribute to software testing within the team as needed to ensure sprint goals are met.
 
Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everting we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect: 

• An opportunity to truly impact health globally  
• A flexible work environment  
• A comprehensive onboarding experiences
• An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply, please click here.
• The deadline to receive your application is 14th Aug, 2023.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Read our Recruitment Privacy Statement

Tuesday, August 1, 2023 Category: Jobs

Tuesday, August 1, 2023

糖尿病患者に対する手術前、手術中および手術後の厳格な血糖管理にはどのような効果があるのか 要点 - 厳格な血糖管理は血糖値の低下を招き、「低血糖」（健康な血糖値を下回ること）のリスクを高める可能性がある。 - 厳格な血糖管理によって死亡率は低下しない。また、感染症および腎障害のリスクは減少せず、入院期間や集中治療室の滞在期間が短縮されることもない。しかし、厳格な血糖管理によって心血管障害のリスクが減少する可能性がある。 - さまざま種類の手術に対する厳格な血糖管理の効果を明らかにするには、さらに多くの研究が必要である。 これまでにわかっていること 周術期とは、病棟への入院、麻酔、術後の回復など、患者ひとりの手術前、手術中、手術後の各段階を網羅した外科手術前後の期間のことである。糖尿病患者は、通常よりも手術後の合併症のリスクが高い。糖尿病は術後の合併症の危険因子としてよく知られており、入院期間の延長、医療資源の利用の増加、さらに死亡率の上昇を引き起こす。最も重大な合併症のひとつが、手術前後の感染症リスクの増加である。しかし、糖尿病患者の手術に伴うリスクを減らすために、周術期に、通常よりも厳格な血糖管理を目指すことが、従来の血糖値を目標とするよりも優れているかどうかは明らかになっていない。 知りたかったこと 前回のレビューの結果は、糖尿病患者に対する手術中の血糖管理方法について明らか...

機能性月経困難症の治療としての配合経口避妊薬（OCP） 論点 コクランは月経痛（生理痛、月経困難症とも呼ばれる）の治療に対する配合経口避妊薬（OCP）の有効性と安全性に関するエビデンスをレビューした。 背景 OCPは月経痛の治療薬としてしばしば使用されているが、その効果についてのエビデンスは不確かであった。 研究の特徴 OCPの効果をプラセボ（偽薬）、他のOCP、痛みや炎症を抑える非ステロイド性抗炎症薬のいずれかと比較した21件のランダム化比較試験（2つ以上の治療群のうちひとつに無作為に割りつける臨床試験）を特定した。これらの研究には3,723人の女性が含まれていた。ほとんどの女性は、少なくとも中等度以上の痛みを伴う月経痛があった。11件の研究がOCPの製薬会社から資金を提供されていた。2023年3月にデータベースを検索した。 主な結果 OCPとプラセボの比較 OCPは、月経痛のある女性において、プラセボと比較して、月経困難症総合スケール（0～6の範囲）で0.7～1.3ポイント痛みを軽減する（588人の女性を対象とした6件の研究；質の高いエビデンス）。改善を「はい／いいえ」で評価した6件の研究では、OCPは痛みを軽減する可能性があることが示された。プラセボでは28％の確率で症状が改善し、OCPでは37％～60％の確率で改善する可能性がある（質の低いエビデンス）。 OCPは副作用の...

すべての長期介護環境における身体拘束を防止および削減するための介入 背景 身体拘束（PR）とは、好きな位置に自由に体を動かせないようにする器具である。例として、ベッド柵、ベルト、固定式テーブルなどがあり、これらはベッドや椅子から転落することを防止する。PRは、認知症や歩行困難のある高齢者が、介護施設や自宅で介護を受ける際に、ごく一般的に使用されている。PRを使用する主な理由は、偶発的な転倒や転倒によるけがを防ぐため、あるいは他人の部屋への侵入や、徘徊などにより高齢者自身や他人を危険にさらすことを防ぐためである。 しかし、転倒や転倒によるけがの予防に対するPRの有効性については疑問視されている。実際、体を動かさない時間を増やすことで、歩行障害を悪化させ、転倒のリスクを高める可能性がある。また、恐怖感や怒り、不快感を増やし、幸福度を低下させる可能性もある。その他の予期しない事象には、褥瘡や失禁のリスクの増加、PR自体によるけがなどがある。国によっては、PRの使用はほとんどの状況において違法であり、ガイドラインにより、その使用を減らすか中止することが推奨されている。 何を調べようとしたのか？ 介護施設または自宅において長期介護を受けている高齢者に対するPRの使用の防止または削減のために、どのような介入が最も効果的であるかを明らかにしたかった。PRの使用を防止および削減するための介入には...

新規抗精神病薬ブレクスピプラゾールのうつ病治療における利益と有害性は、ダミー錠や抗うつ薬と比較した場合、どのようなものか？ 要点 - 抗うつ薬に追加されたブレクスピプラゾールは、抗うつ薬に追加されたプラセボ（ダミー錠）よりもうつ病の症状を軽減するのに優れている。 - ブレクスピプラゾールは、体重増加やアカシジア（常に動きたくなるような落ち着きのなさ）と関連することが多い可能性がある。 うつ病とは？ うつ病は一般的な精神疾患で、気分の落ち込み、喜びを感じられない、睡眠障害、体重減少、疲労や気力の低下、会話や動作が遅くなる、無価値感や過剰な罪悪感、集中力の欠如、自殺を考えるようになるという症状を引き起こす。うつ病と診断されるには、気分の落ち込みや快感の喪失など、これらの症状のうち5つ以上を少なくとも2週間以上経験する必要がある。 どのように治療するか？ うつ病の症状が軽度でない限り、治療の最初の選択肢は抗うつ薬であるが、抗うつ薬が初めて処方された場合に効果があるのは半数程度である。抗うつ薬だけではうつ病の治療が十分でない場合、抗うつ薬の効果を助けるために別の薬を追加するという選択肢もある。その他の選択肢としては、抗うつ薬を別の抗うつ薬に変更する、会話療法、電気パルスによる脳への刺激などがある。ブレクスピプラゾールは新しい薬で、単独では効かない抗うつ薬に追加して使用することができる。ブ...

Cochrane Review reveals vital role of supportive managers to minimise physical restraint use in care homes

A new Cochrane review finds that the use of physical restraints on care home residents can be reduced without increasing the risk of falls, when frontline care staff are empowered by supportive managers.

Physical restraints are devices that restrict freedom of movement and are frequently used in residential care homes, such as nursing homes and assisted living facilities. Examples are bed rails or belts that prevent residents from getting out of bed unassisted. These restraints are ethically problematic as they are mostly used in people with dementia who are often unable to consent to their use.

Physical restraints are often intended to prevent falls and fall-related injuries. However, the benefits are often small and come with important negative consequences. For example, the restriction of movement can have negative implications on physical functioning and mobility, actually increasing the risk of falls and care dependency. The measures can also trigger or increase fear or aggressive behaviour. For this reason, guidelines and experts recommend avoiding physical restraints in residential care settings.

But how can this be implemented in practice? A Cochrane Review, first published in 2011 and recently updated to reflect the latest research, analyses the scientific evidence on interventions and strategies to reduce the use of restraints. The team of authors, led by Ralph Möhler of the University Hospital Düsseldorf, identified 11 studies with a total of 19,003 participants, evaluating different intervention approaches.

In their evaluation, the authors found the best evidence for organizational interventions, which were investigated in 4 studies with a total of 17,954 participants. Organizational interventions to reduce the use of restraints consist of different components to function as a package. They aim to improve knowledge, skills, and strategies to prevent restraint use among both frontline care staff and managers. In three studies, employees designated as ‘champions’, were trained to develop and implement individual strategies to prevent the use of restraints within their facilities.  Managers supported this, including by relieving them of other activities and provide them with sufficient time for their tasks.

Such interventions probably reduce the number of residents with physical restraints in nursing homes by 14%. There was no overall change in the number of residents with falls or fall-related injuries and there was no increase in the prescription of psychotropic medication. In addition, there was no evidence of adverse effects of the interventions. Based on the study data, the authors calculated that the number of residents with physical restraints could be reduced from 274 to 236 per 1000 individuals, if such interventions were implemented. Focusing on changes on the organisational level seems to be important for achieving long-term effects.

Six studies examined educational interventions addressing staff knowledge and attitudes regarding the use of restraints. The results of these studies were inconsistent and some of the studies had methodological limitations. Therefore, no clear conclusion on the effects of educational interventions can be drawn.

"The results of this review show that physical restraints in nursing homes can be reduced without increasing falls or fall-related injuries,” Ralph Möhler, lead author of the review.

“There is no evidence in the reviewed studies that psychotropic medications were prescribed more often. However, education for frontline staff alone doesn’t seem to be enough; the support of care home managers plays a decisive role."

• Read the plain language summary and full Cochrane Review

Friday, July 28, 2023

Spectacles that are marketed to filter out blue light probably make no difference to eye strain caused by computer use or to sleep quality, according to a Cochrane review of 17 randomised controlled trials of the best available evidence so far. 

Nor did the review, led by authors from the University of Melbourne and published in the Cochrane Database of Systematic Reviews, find any evidence that blue-light filtering lenses protect against damage to the retina, the light-sensitive tissue at the back of the eye.

Blue-light filtering lenses, also known as blue-light blocking spectacles, have been increasingly prescribed or recommended, often by opticians, since the early 2000s. An Australian survey-based study in 2018 found that, of the 372 optometrists who responded, 75% prescribed these lenses despite acknowledging limitations in the evidence to support their use.  

The Cochrane Eyes and Vision team set out to assess the effects of blue-light filtering lenses compared with non-blue-light filtering lenses for improving visual performance, providing protection to the retina and improving sleep quality. They analysed data from all the randomised controlled trials they could find on the topic and found 17 trials from six countries. Of the 17 trials, 12 were conducted in Australia, the Czech Republic, Japan, Norway, the USA and the UK. Five studies did not report the country in which the trial was conducted. Most of the studies were published after 2010, suggesting a growing research interest in blue-light filtering lenses over the past decade. The numbers of participants in individual studies ranged from five to 156, and the period of time over which the lenses were assessed ranged from less than one day to five weeks.

The senior author of the review is Associate Professor Laura Downie, Dame Kate Campbell Fellow and Head of the Downie Laboratory: Anterior Eye, Clinical Trials and Research Translation Unit, at the University of Melbourne, Victoria, Australia.

She said: “We found there may be no short-term advantages with using blue-light filtering spectacle lenses to reduce visual fatigue associated with computer use, compared to non-blue-light filtering lenses. It is also currently unclear whether these lenses affect vision quality or sleep-related outcomes, and no conclusions could be drawn about any potential effects on retinal health in the longer term. People should be aware of these findings when deciding whether to purchase these spectacles.”

However, the quality and duration of the studies also needs to be considered, she said. 

“We performed the systematic review to Cochrane methodological standards to ensure the findings are robust. However, our certainty in the reported findings is limited by the quality of the available evidence. The short follow-up period restricted our ability to consider potential longer-term outcomes.”

The first author of the review, Dr Sumeer Singh, a postdoctoral research fellow in the Downie Laboratory, said: “High-quality, large clinical research studies with longer follow-up in more diverse populations are still required to ascertain more clearly the potential effects of blue-light filtering spectacle lenses on visual performance, sleep and eye health. They should examine whether efficacy and safety outcomes vary between different groups of people and using different types of lenses.”

The review did not find any consistent reports of adverse side effects from using blue-light filtering lenses. Any effects tended to be mild, infrequent and temporary. They included discomfort wearing the spectacles, headaches and lower mood. These were likely to be related to the wearing of spectacles generally, as similar effects were reported with non-blue-light filtering lenses.

Prof. Downie said: “Over the past few years, there has been significant debate about whether blue-light filtering spectacle lenses have merit in ophthalmic practice. Research has shown that these lenses are frequently prescribed to patients in many parts of the world, and a range of marketing claims exist about their potential benefits, including that they may reduce eye strain associated with digital device use, improve sleep quality and protect the retina from light-induced damage. The outcomes of our review, based on relatively limited data, show that the evidence is inconclusive and uncertain for these claims. Our findings do not support the prescription of blue-light filtering lenses to the general population, and these results are relevant to a broad range of people, including eye care professionals, patients, researchers and the broader community.”

The potential mechanisms by which blue-light filtering lenses might be able to help with eye strain, sleep and protecting the retina are not known. One rationale for claims about the benefits of these lenses is that modern digital devices such as computers and smart phones emit more blue light than traditional lighting sources, and are being used for longer, and closer to bedtime. 

Dr Singh said: “The amount of blue light our eyes receive from artificial sources, such as computer screens, is about a thousandth of what we get from natural daylight. It’s also worth bearing in mind that blue-light filtering lenses typically filter out about 10-25% of blue light, depending on the specific product. Filtering out higher levels of blue light would require the lenses to have an obvious amber tint, which would have a substantial effect on colour perception.”

• Read the plain language summary and full review in the Cochrane Library 
• Visit the Cochrane Eyes and Vision website
• Read Evidently Cochrane blog post 'Blue light-filtering lenses: useful for eye strain, sleep, & eye health? Here’s the evidence'

Monday, August 21, 2023

超早産児または極低出生体重児の壊死性腸炎予防のためのプロバイオティクス 本レビューの論点 プロバイオティクスを超早産児や極低出生体重児に与えることで、壊死性腸炎を防ぐことができるか 背景 超早産児（8週以上早く生まれた児）や極低出生体重児（出生時の体重が1.5 kg未満の児）は、壊死性腸炎を発症するリスク（危険）がある。壊死性腸炎は、乳児の腸の内壁の組織が炎症を起こし、死に至る重篤な疾患である。この疾患は、死亡、重篤な感染症、長期障害、発達障害につながる可能性がある。 知りたかったこと 壊死性腸炎を予防する1つの方法として、プロバイオティクス（潜在的に有益なバクテリアや酵母を含むダイエタリーサプリメント（栄養補助食品））をミルクに添加することが考えられる。我々は、プロバイオティクスの補充が超早産児や極低出生体重児にベネフィット（有益性）があるかどうかを検証したいと考えた。具体的には、プロバイオティクスの補充が、プラセボ（ダミー治療）や無治療よりも改善効果があるかどうか検証したいと考えた。 - 壊死性腸炎 - あらゆる理由による死亡 - 重篤な感染症 - 出生からの入院期間 - 神経発達障害 実施したこと 超早産児・極低出生体重児の壊死性腸炎予防のためのプロバイオティクスの使用を検討したランダム化比較試験（参加者を無作為に2つ以上の治療群のいずれかに割り当てる試験）を同定するために...

「微小血栓」が新型コロナウイルス感染症の罹患後症状（いわゆる後遺症）を引き起こすというエビデンスは何か、また、血漿交換による微小血栓の除去は正当化されるのか？ 要点 1．「微小血栓」という用語は、新型コロナウイルス感染症(COVID-19)後遺症の患者で調査されている粒子に対する正しい用語ではない。「アミロイド・フィブリン粒子」と呼ぶ方が適切である。 2．アミロイド・フィブリン粒子は、健康な人にも他の病気の人にも見られるというエビデンスがある。つまり、COVID-19後遺症に限られたものではない。 3．患者は、プラセボ（ダミー）を比較対象とした、適切なランダム化臨床試験（参加者を2種類以上の治療群のいずれかに無作為に割り当てるタイプの試験）で得られた知見にもとづくことなく、アミロイド・フィブリン粒子の除去を目的とした血漿交換を受けるべきではない。 何を調べようとしたのか？ COVID-19後遺症（「ロングCOVID」と呼ばれることもある）とは、COVID-19に感染してから少なくとも12週間が過ぎた後に、患者がさまざまな症状を経験する状態を指す。症状の重さには幅があり、疲労、脳霧（ブレイン・フォグ）、頭痛などが含まれ、生活の質(QOL)の低下につながる。COVID-19後遺症の原因については議論がある。一つの説は、血液中の小さな血栓が原因であるというもので、この血栓を調査した一連...

新型コロナウイルス感染症患者に対する抗血小板薬による治療は有効か？ 要点 抗血小板薬は、致死的となる血管内における血栓形成（「血栓イベント」）を予防可能な薬剤の1つである。抗血小板薬は、新型コロナウイルス感染症(COVID-19)の入院患者において、血栓イベントをわずかに減少させるが、プラセボ（偽の治療）や標準治療と比較して、死亡、臨床的悪化、COVID-19の改善には影響がない可能性がある。 しかし、抗血小板薬は、重篤な望ましくない作用（有害事象）をわずかに増加させ、大出血事象を増加させる可能性がある。 外来患者の場合、同様に抗血小板薬は血栓イベントをわずかに減少させるが、死亡または重篤な有害事象にはほとんど、または全く差がない可能性があり、また入院や死亡、大出血事象におけるエビデンスは非常に不確実である。 また、14件の研究は未完了であり、他の3件の研究結果はまだ得られていない。 抗血小板薬とは何か？ 抗血小板薬は、血液が血栓と呼ばれるゲル状の物質に変化する現象（「血栓イベント」と呼ばれる）を防止する薬剤の一つである。抗血小板薬は主に経口投与で使用され、通常、血栓症のリスクが高い患者（すでに血栓症の既往がある患者や、血栓ができやすい患者）に投与される。 血栓は脳卒中、冠状動脈性心臓病、足の血行不良、足の血栓症、および肺循環の血栓による閉塞（塞栓症）を引き起こし、息切れや心不全...

統合失調症がある人における持続的攻撃行動または激越に対する認知行動療法＋標準治療と標準治療の比較 統合失調症がある人の攻撃性や興奮の治療において、認知行動療法は従来の治療よりも優れているか？ 要点 - 認知行動療法が統合失調症がある人の攻撃性に有効であるという十分な質の高いエビデンスは見つからなかった。信頼できる結果を提供するには不十分な参加者が登録されている研究が、2件しか見つからなかった。 - 認知行動療法の利益と潜在的有害性をよりよく推定するためには、より大規模でよく計画された研究が必要である。 統合失調症がある人における攻撃性の重要性は？ 統合失調症は、思考過程、知覚、情動反応、社会的相互作用の障害を特徴とする精神障害である。典型的には持続性で、重篤な障害を伴うこともある。統合失調症がある人における攻撃性（自己攻撃性と他者攻撃性）のリスクはまれであり、ごく少数に限定されるが、もし攻撃性があれば、傷害や死亡のリスクを増大させ、病気の負担を増大させる。認知行動療法は、機能不全に陥った思考に挑戦することを目的とし、精神衛生や感情障害の改善に用いられる。統合失調症の持続的な症状に対して有益な効果を示しており、統合失調症治療における薬物療法の上乗せ療法としての使用は治療ガイドラインで支持されている。しかし、攻撃的な行動をとる統合失調症がある人に対して、認知行動療法を標準治療に加える...

Cochrane UK is proud to host Cochrane’s Colloquium at the Queen Elizabeth II Centre (QEII) in London, UK from 4-6 September 2023. The countdown has begun, but there is still time to register and be part of this enriching experience! 

We spoke with Sabrina Khamissa, Cochrane's Event Support Officer, who shares the measures taken to create an environmentally responsible Colloquium. 

A central location with many transportation options
Hi Sabrina, we're thrilled about Cochrane's upcoming in-person event in London, UK, and the central location you've chosen is truly exciting. Can you share some insights into how the location was selected and its significance in terms of environmental considerations?

"Certainly! When deciding on the location for #CochraneLondon, we took several factors into account, including our community's geographical distribution. Since a substantial portion of our attendees are based in Europe, hosting the conference in the UK made sense as it encourages participants to opt for more sustainable travel options, particularly trains, which can significantly reduce the event's overall carbon footprint.

London was an ideal choice for its vibrant atmosphere and outstanding public transportation links. By placing the conference at the heart of the city, we aimed to minimize the need for private vehicles and promote the use of eco-friendly transportation alternatives. The venue's close proximity to multiple tube stations and pedestrian-friendly surroundings provides attendees with ample opportunities to choose greener commuting options. We invite all attendees to participate in the Anne Anderson Walk and see the many spots of medical history and London landmarks that are just steps away from the venue."

Sustainability at the heart of the venue choice
The Queen Elizabeth II Centre, where the Colloquium is set to take place, indeed appears to be a fantastic location. Can you elaborate on what specifically drew you to this venue and how its commitment to sustainability aligns with Cochrane's environmental goals?

"When looking at venues we had a checklist of specific requirements, placing a strong emphasis on environmental stewardship and a formal sustainability policy. The Queen Elizabeth II Centre stood out as an exceptional choice, impressing us with its diverse green initiatives aimed at ensuring minimal ecological impact. These initiatives encompass responsible waste management, energy-efficient systems, water conservation efforts, and even hosting 10,000 bees on the fourth-floor area—an inspiring commitment to urban biodiversity.

 

Attendees will see our venue choice play out in very practical ways. The Centre's strategic location allows easy accessibility, with the majority able to walk or use public transportation from their hotels. Moreover, we are dedicated to reducing single-use plastic, eliminating items like cups and straws during the event. By incorporating LED motion-sensitive lighting and maximizing natural light, energy conservation is prioritized. In our efforts to minimize paper usage, we will be using lots of digital signage ver printed signs, contributing to a more sustainable and eco-conscious conference experience for everyone at #CochraneLondon."

Delicious and environmentally friendly food choices
No matter the event, food selection and taste is always something attendees comment on afterwards. Is this something that was considered?

"It was! We understand that the dining experience is a significant aspect of any in-person event, and we wanted to ensure that attendees not only enjoyed delicious meals but also made environmentally conscious choices. The venue has a British-first policy for sourcing ingredients, to support local farms and growers but also to make sure they are using seasonal produce and are reducing carbon footprints.  Only fair-trade coffee and teas are served. And we have taken a step further by selecting a menu that emphasises plant-based meals and are going with 'bowl food' which helps reduce waste.

Rest assured, the taste and quality of the meals served at #CochraneLondon are of paramount importance to us, and we have thoughtfully selected food options that not only delight the taste buds but also align with our commitment to environmental responsibility."

A shift from traditional swag bags and branded items
It's really reassuring that a lot of thought has gone into many aspects of the venue and experience that are environmentally conscious. One typical aspect of an academic conference is swag or branded items that they get at the start of the conference. What can attendees expect?

"Rather than traditional swag bags, we've taken an eco-conscious route by introducing a print-on-demand store. This innovative approach allows attendees to curate their own experience by selecting and purchasing limited-edition Cochrane items beforehand. This not only reduces unnecessary waste but also ensures that participants receive merchandise they truly value and intend to use. The print-on-demand store offers an exciting range of items, including tote bags, t-shirts, and mugs, which attendees can choose to purchase for their convenience during the conference or as cherished souvenirs of the event.

Even the smallest details have been thoughtfully considered from an environmental perspective. When attendees arrive at the registration desk, they will receive a lanyard and name badge. Here, too, we have opted for a sustainable approach, providing recyclable name badges that will be printed on location. This decision further minimizes our ecological footprint while ensuring that attendees can proudly display their identification throughout the conference in an eco-friendly manner."

We hope you enjoyed this insightful glimpse into #CochraneLondon's integration of sustainability. By showcasing how even the simplest choices can culminate in a profound impact, the Cochrane Colloquium sets a noteworthy example for fostering greener and more responsible event experiences worldwide. 

Join us at #CochraneLondon as we unite to propel our shared vision and build a more sustainable world, advancing together for trusted evidence. See you there!

• Visit the Colloquium website

Monday, July 31, 2023

Cochrane UK is proud to be hosting Cochrane’s Colloquium at the Queen Elizabeth II Centre (QEII) in London, UK from 4-6 September 2023. The countdown has begun, but there is still time to register and be part of this enriching experience! 

You can now explore the full programme and curate your own Colloquium experience. Take advantage of this opportunity to select the sessions you're most eager to attend and tailor your schedule to your needs and interests. Though it won't guarantee you a seat, it will help us allocate the bigger rooms for the most popular sessions. Once you have picked your sessions, you can add your chosen session to your Apple, Google, or Outlook calendar.

With the theme “Forward together for trusted evidence”, the 2023 Cochrane Colloquium is set to be a groundbreaking event, uniting individuals from diverse backgrounds in a journey of learning, networking, and unforgettable experiences. Immerse yourself in a captivating lineup of plenary talks, workshops, posters, oral presentations, and meetings that encompass a vast spectrum of topics and issues in evidence-based health care.

The colloquium isn't just about the academic content – it's about building connections and creating unforgettable memories. Engage in enriching networking events, ‘take a break’  with some fun social activities, and discover the wisdom of human 'books' at our thought-provoking Library of People. You'll also have the chance to join your colleagues and new Colloquium friends at an unforgettable social gathering at the iconic Natural History Museum. This event truly has something remarkable for everyone!

"Cochrane Colloquiums are more than just an academic gathering; they are a celebration of progress, collaboration, and camaraderie," says Sabrina Khamissa, Cochrane's Event Support Officer.  "The #CochraneLondon program is a testament to this spirit, offering a diverse and engaging lineup of sessions led by some of the most prestigious experts globally. From groundbreaking methodology in evidence synthesis to insightful discussions on knowledge translation, there's something for everyone. We are thrilled to welcome you all to this transformative experience that will shape the future of Cochrane and evidence-based healthcare on a global scale. Together, let's forge ahead for trusted evidence and make a lasting impact on the world of healthcare!"

As anticipation builds, we can't wait to welcome you to London and unite the community once again! Don't miss out on this transformative event, where trusted evidence takes center stage and lasting connections flourish.

Find out more:

• View and update your schedule
• Visit the Colloquium website
• List of Plenary speakers
• ‘Take a break’ activities
• The social event at the Natural History Museum
• The Anne Anderson walk

Get in touch: colloquium@cochrane.org

Tuesday, July 25, 2023

Cochrane UK is hosting Cochrane’s Colloquium at the Queen Elizabeth II Centre (QEII) in London, UK from 4-6 September 2023. With the theme “Forward together for trusted evidence”, the 2023 Cochrane Colloquium is set to be a groundbreaking event with a mix of learning, networking, plenary speakers; a unique and memorable experience at one of London's most renowned venues.

At Cochrane, nurturing aspiring minds and supporting professionals embarking on their career journey is part of the work we do. Our commitment is evident through initiatives like the Cochrane Early Career Professionals Network, Cochrane US Mentorship,  Cochrane International Mobility, and the student pathway to Cochrane Membership. Among these opportunities, the Cochrane Colloquium stands out as an inspirational experience not to be missed. This three-day event provides an enriching platform to learn, connect, and grow. Delve into a diverse range of sessions and engaging activities, fueling your knowledge and expanding your professional network in the world of evidence-based healthcare.

Exciting sessions relevant to students and early career professionals: 

• Putting evidence into practice - A satellite event for students and healthcare professionals: A half-day event on the Sunday ahead of the Colloquium. Learn about Cochrane Reviews, evidence-based practice, fraudulent research and trustworthy evidence. This interactive event is for students and healthcare professionals from any healthcare discipline that feels there is a gap in their current skill set. You may register just for this event or add this event to your colloquium experience. 
• Meet the Cochrane CEO and Editor-in-Chief - Networking doesn't get any more exciting than this! Meet some of the top people in Cochrane, ask questions, and interact in a casual environment. 
• Meet the Author Journey Lead - Find out more about how to propose a new or updated review, and what the topic experts that consider proposals are looking for.
• Forward Together: new ways to participate in Cochrane - Learn about all the many ways you get in involved in Cochrane's ecosystem!
• Cochrane-Wikipedia Initiative - Join this hands-on workshop to help improve the health content that people are accessing online.
• Interpreting systematic review findings - Join this small-group workshop to learn about how to translate research and support decision-making in health care. 
• Library of People - Just like a regular library where you check out books, come along to speak to someone you wouldn’t normally meet and listen to their story.

This is just a small section of the diverse programming offered at Cochrane London. There are plenty of short oral sessions, longer plenary sessions, posters, social events, and workshops. Over three days you will be able to immerse yourself in the latest advancements in systematic review methodology and network with the leading experts in evidence-based medicine. 

Don't miss out on this unique opportunity to be part of Cochrane's Colloquium and contribute to the pursuit of trusted evidence. Register today and let's move forward together towards a healthier future! 

Cochrane Colloquium
4-6 September 2023
London, UK
Registration fees with information about student discount and one-day registration
Full programme

 

Tuesday, August 1, 2023

Cochrane UK is hosting Cochrane’s Colloquium at the Queen Elizabeth II Centre (QEII) in London, UK from 4-6 September 2023. With the theme “Forward together for trusted evidence”, the 2023 Cochrane Colloquium is set to be a groundbreaking event with a mix of learning, networking, plenary speakers; a unique and memorable experience at one of London's most renowned venues. On the evening of Tuesday, September 5th, delegates will gather at the iconic Natural History Museum in South Kensington, for an extraordinary social event.

After the museum closes its doors to the public, Cochrane Colloquium attendees will be granted exclusive access to the main entrance area, Hintze Hall. This hall has dramatic Romanesque arches and a majestic staircase. You’ll have the opportunity to explore the surrounding museum specimens in the Hall and dance beneath the suspended 25-meter blue whale skeleton named ‘Hope’.

In the spirit of giving back, Cochrane Colloquium organizers have requested a £15 donation during registration, to be given to St. Mungo's, a national charity based in London that works to prevent homelessness and aid individuals in their journey to recover from it. By encouraging donations, we hope to minimize non-attendance and food waste, while positively impacting the community.

"One of the most anticipated aspects of every Cochrane Colloquium is the opportunity to gather with colleagues, share laughter, and dance the night away,” says Martin Burton, Director of Cochrane UK. “We are excited to host this year's social event at the Natural History Museum, which sets the stage for an unforgettable evening. Prepare to be captivated by the perfect blend of British charm, vibrant UK music, and the sheer delight of coming together with colleagues. We are confident that this year’s social event will create cherished memories for all who join us!"

The dress code is slightly ‘posher’ than the conference – so deerstalker hats and fascinators are welcome! Attendees will enjoy some delicious bowl food and canapés while the dance floor beckons. Embracing the tradition of previous Colloquiums, participants will sway to music representative of the host country. UK is rich in music tradition, from regency ballroom Contra Dancing to British punk rock. No prior dance experience is necessary; simply join in the fun on the dance floor!

Attendees can look forward to immersing themselves in the rich history and grandeur of the venue, enjoying the vibrant atmosphere, and creating lasting memories alongside colleagues from around the world. To get attendees excited and ready to dance the night away, an exclusive Spotify playlist has been created for #CochraneLondon. You can also contribute your favourite UK songs on social media using the event's official hashtag, #CochraneLondon. 

Cochrane Colloquium Social Event 
Tuesday 5 September 2023
7:30 pm
Natural History Museum
Address: Cromwell Rd, South Kensington, London SW7 5BD, UK
Provided: Bowl food, canapés, desserts, drinks
Dress Code: posh/spiffy casual
Guests: If you would like to bring guests, you’re welcome to buy additional tickets at £75 each (including VAT). To do so, please email registration@cochrane.org and let them know how many extra tickets you would like.

•       Visit the Colloquium website

Friday, July 28, 2023

Founded 30 years ago in Oxford, Cochrane UK was Cochrane’s first geographic group. Cochrane now has over 130 such groups across the world, working in-country to support the production, dissemination and use of evidence to guide decision-making in health and care.

In March 2024, Cochrane UK’s current contract with the National Institute for Health and Care Research (NIHR), hosted by the Oxford University Hospitals NHS Foundation Trust, will come to an end. As a result, Cochrane UK will shortly be seeking a new funder and host institution.

Catherine Spencer, Chief Executive of Cochrane, said: “Cochrane UK has been at the forefront of Cochrane throughout its 30 year history and was our first geographic group. Cochrane UK has made an extraordinary contribution to evidence-based health and care, I extend my heartfelt thanks to the incredible team in Oxford – past and present – for all they have done.

“As we look to the future, there is an exciting opportunity for a new institution to host Cochrane UK and help more people to benefit from health and care evidence. We will be reviewing what is needed in the UK before we begin a selection process. But I would encourage anyone interested in hosting Cochrane UK at their institution to get in touch with me in the meantime.”

Last November it was announced that in September 2023, Cochrane UK’s Director, Martin Burton, will be moving to Cambridge to become Master of Sidney Sussex College. This summer, Therese Docherty will take on the role of Acting Director, having managed Cochrane UK’s operations for nine years.

Catherine Spencer said: “Martin’s exceptional leadership at Cochrane UK has been truly inspiring. His dedication to advancing evidence-based healthcare and improving patient outcomes has left an indelible mark on our organization and the broader medical community. He has shown a peerless talent for fostering collaboration, supporting people and driving impactful work. As he embarks on the next chapter, we extend our heartfelt gratitude for his invaluable contributions and wish him all the best with his new role.”

Martin Burton said: “I have thoroughly enjoyed my time as Director of Cochrane UK, in particular for the opportunity it has given me to work with an excellent team here, and with so many wonderful Cochrane contributors in the UK and around the world. Cochrane UK is in safe hands and I look forward to hearing more about Cochrane’s future plans. The world needs high-quality evidence in general, and synthesised evidence in particular, now more than ever before. These are exciting times as Cochrane adapts and flexes to meet the new challenges ahead.”

Wednesday, July 19, 2023

プライマリ・ヘルスケアの統合に対する医療従事者の認識および経験：質的エビデンスのスコーピングレビュー プライマリ・ヘルスケア（PHC）の統合とは何か？ プライマリ・ヘルスケア（PHC）の統合とは、これまで別々に提供されていたPHCのサービスを統合することである。その目的は、より良い医療を容易に受けられるようにし、限られた医療資源をより効率的に活用できるようにすることである。 なぜ医療従事者の認識や経験を知ることが重要なのか？ PHCの統合は多くの国で実施されており、種々の成功が得られている。医療従事者は、このような医療サービスの変容の成功に関して影響を与えることができる。PHCの統合に関する医療従事者の認識や経験を知ることは、医療従事者がその実施およびその成否にどのように影響するかを理解することに役立つ。 本スコーピングレビューの目的は何か？ 本スコーピングレビューでは、PHCの統合に関する医療従事者の認識や経験に関する質的研究（数値データのない研究）を検索し、マッピングを行った。そして、この分野における今後の系統的レビューや調査研究の参考となる研究を特定することを目的とした。 どのようにエビデンスを特定し、マッピングを行ったのか？ 2020年7月28日までに発表された、PHCの統合に関する医療従事者の認識や経験について報告されたすべての質的研究について検索を行った。さまざまな研...